Filing Details
- Accession Number:
- 0001237899-20-000010
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-14 16:10:51
- Reporting Period:
- 2020-02-13
- Accepted Time:
- 2020-02-14 16:10:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 872589 | Regeneron Pharmaceuticals Inc. | REGN | Pharmaceutical Preparations (2834) | 133444607 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1437435 | Marc Tessier-Lavigne | 777 Old Saw Mill River Road Tarrytown NY 10591 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-02-13 | 5,000 | $57.11 | 6,830 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-13 | 5,000 | $400.03 | 1,830 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-02-13 | 9,279 | $50.91 | 11,109 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-13 | 637 | $398.71 | 10,472 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-13 | 800 | $399.41 | 9,672 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-13 | 7,842 | $400.16 | 1,830 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-02-13 | 9,279 | $0.00 | 9,279 | $50.91 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-02-13 | 5,000 | $0.00 | 5,000 | $57.11 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2021-11-18 | No | 4 | M | Direct | |
| 0 | 2022-01-03 | No | 4 | M | Direct |
Footnotes
- Represents volume-weighted average price of sales of 5,000 shares of Company stock on February 13, 2020 at prices ranging from $400.00 to $400.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
- Represents volume-weighted average price of sales of 637 shares of Company stock on February 13, 2020 at prices ranging from $398.39 to $398.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
- Represents volume-weighted average price of sales of 800 shares of Company stock on February 13, 2020 at prices ranging from $399.00 to $399.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
- Represents volume-weighted average price of sales of 7,842 shares of Company stock on February 13, 2020 at prices ranging from $400.02 to $400.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
- The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
Billionaire Hedge Funds
